E. Musch
Impact in
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
- Antibiotics Pharmacokinetics and Efficacy
- Hepatology top 10%
- Hepatitis C virus research
Papers in
- Co-authors
- U. Loos (14 shared papers)Michel Eichelbaum (7 shared papers)J.Chris Jensen (2 shared papers)Gerd Mikus (1 shared paper)T. Andus (2 shared papers)Robert Löfberg (3 shared papers)Arezou Zargari (2 shared papers)Gerd E. Von Unruh (2 shared papers)
In The Last Decade
E. Musch
45 papers receiving 585 citations
Peers
Comparison fields: 5 of 80
- Pharmacology 78
- Hepatology 60
- Oncology 127
- Infectious Diseases 85
- Immunology 91
Countries citing papers authored by E. Musch
This map shows the geographic impact of E. Musch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Musch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Musch more than expected).
Fields of papers citing papers by E. Musch
This network shows the impact of papers produced by E. Musch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Musch. The network helps show where E. Musch may publish in the future.
Co-authors
The 25 scholars most cited alongside E. Musch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1985 | 120 | |
| 2 | 2005 | 52 | |
| 3 | 2009 | 40 | |
| 4 | 2002 | 40 | |
| 5 | 2012 | 38 | |
| 6 | 2003 | 34 | |
| 7 | 1989 | 33 | |
| 8 | 2007 | 24 | |
| 9 | 2014 | 21 | |
| 10 | 1989 | 19 | |
| 11 | 1985 | 19 | |
| 12 | 1987 | 19 | |
| 13 | 1988 | 18 | |
| 14 | 1982 | 14 | |
| 15 | 2006 | 12 | |
| 16 | 1988 | 12 | |
| 17 | 2003 | 11 | |
| 18 | Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. | 1999 | 10 |
| 19 | 1990 | 9 | |
| 20 | Successful application of highly purified natural interferon alpha (multiferon) in a chronic hepatitis C patient resistant to preceding treatment approaches. | 2004 | 9 |
About E. Musch
E. Musch is a scholar working on Oncology, Genetics, Infectious Diseases, Surgery and Epidemiology, having authored 53 papers that have together received 613 indexed citations. Recurring topics across this work include Hepatitis C virus research (5 papers), Inflammatory Bowel Disease (5 papers), Drug Transport and Resistance Mechanisms (5 papers), Pharmacogenetics and Drug Metabolism (4 papers), Drug-Induced Hepatotoxicity and Protection (4 papers), Tuberculosis Research and Epidemiology (4 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and HIV/AIDS drug development and treatment (3 papers). The work is most often cited by research in Pharmacology (78 citations), Hepatology (60 citations), Oncology (127 citations), Infectious Diseases (85 citations) and Immunology (91 citations). E. Musch has collaborated with scholars based in Germany, Sweden and Hungary. Frequent co-authors include U. Loos, Michel Eichelbaum, J.Chris Jensen, Gerd Mikus, T. Andus, Robert Löfberg, Arezou Zargari, Gerd E. Von Unruh, Martina E. Spehlmann and Filip Závada. Their work appears in journals such as Journal of Molecular Medicine, Cancer Chemotherapy and Pharmacology, Clinical Gastroenterology and Hepatology, Oncology and Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.